Annotation Detail

Information

Associated Genes: STK11
Associated Variants: STK11 MUTATION
STK11 MUTATION
Associated Disease: lung adenocarcinoma
Source Database: CIViC Evidence
Description: In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and OS compares to KRAS only and KRAS-TP53 Mutant Patients. This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/6441
Gene URL: https://civic.genome.wustl.edu/links/genes/5534
Variant URL: https://civic.genome.wustl.edu/links/variants/715
Rating: 4
Evidence Type: Predictive
Disease: Lung Adenocarcinoma
Evidence Direction: Supports
Drug: Atezolizumab,Nivolumab,Pembrolizumab
Evidence Level: B
Clinical Significance: Resistance
Pubmed: 29773717

Drugs